Breast cancer and ovarian cancer are very common cancers. Therefore, early diagnosis of predisposition to diseases, including molecular genetic, is crucial.
With mutation of the BRCA 1,2 genes, the protective, antitumor ability of cells is significantly reduced, which in turn can lead to an increase in the occurrence of the carcinogenesis process. At the same time, the statistical risk of developing breast and ovarian cancer increases several times. In particular, breast cancer in individual populations increases by 55-65% with the BRCA 1 mutation and by 45% with the BRCA 2 mutation more often than in the usual population group*.
BRCA 1,2 gene mutation test is performed:
-
if relatives have a positive BRCA1,2 test.;
-
with a burdened family history of breast cancer (two or more female relatives with breast cancer under the age of 50 and three or more at any age);
-
early onset of the disease (up to 40 years and younger);
-
multiple forms of a tumor in one breast or in both mammary glands;
-
if a woman has both breasts and ovaries affected;
-
breast cancer in men;
-
with triple negative breast cancer;
-
with combined cancer (for example, pancreatic and ovarian cancer).
(*data from the National Cancer Institute at the National Institutes of Health)
An analysis for the presence of a BRCA 1,2 gene mutation is performed on any given day by blood donation.
